Regenerative medicine uses clinical procedures to repair or replace damaged or diseased tissues and organs, versus some traditional therapies that just treat symptoms.
To realize the vast potential of tissue engineering and other techniques aimed at repairing damaged or diseased tissues and organs, the University of Pittsburgh School of Medicine and UPMC established the McGowan Institute for Regenerative Medicine. The McGowan Institute serves as a single base of operations for the University’s leading scientists and clinical faculty working to develop tissue engineering, cellular therapies, and artificial and biohybrid organ devices.
The McGowan Institute is the most ambitious regenerative program in the nation, coupling biology, clinical science, and engineering. Success in our mission will impact patients’ lives, bring economic benefit, serve to train the next generation of researchers, and advance the expertise of our faculty in the basic sciences, engineering, and clinical sciences. Our efforts proudly build upon the pioneering achievements of the Thomas E. Starzl Transplantation Institute.
While there are certain select therapies based on regenerative medicine principles now in clinical use, much work lies ahead to realize the potential of this growing field. Advances in the underlying science, engineering strategies to harness this science, and successful commercial activities are all required to bring new therapies to patients.
McGowan Institute for Regenerative Medicine
450 Technology Drive
Pittsburgh, PA 15219
The McGowan Institute sponsors a podcast series on regenerative medicine. Listen to some of the world's leading regenerative medicine researchers and physicians talk about their work.
Avista Therapeutics, which recently launched as a spinout of leading health system University of Pittsburgh Medical Center (UPMC), aims to develop innovative gene therapies for rare ophthalmic conditions. The new company announced a partnership with Roche to develop novel AAV gene therapy vectors for the eyes.
Cell-based therapies have long been thought of as an alternative treatment option for patients with a range of diseases caused by organ and tissue failure, inclusive of heart attack, diabetes, corneal blindness, and cystic fibrosis. While great in theory, in practice these therapies show limited clinical success in many applications due to low cell viability after injection, as well as poor retention at the injection site and engraftment into damaged tissue.
A child’s history of depression and concussion within the previous year, along with their race, ethnicity, and sex, can help predict the likelihood of a suicide attempt, according to a new study led by University of Pittsburgh School of Medicine researchers. McGowan Institute for Regenerative Medicine affiliated faculty member David Okonkwo, MD, PhD (pictured), Professor of Neurological Surgery and Director of the Neurotrauma Clinical Trials Center, Director of Neurotrauma and of the Scoliosis and Spinal Deformity Program at UPMC, and Clinical Director of the Brain Trauma Research Center, is a co-author of the study.
With funding from the National Institutes of Health, National Institute of Dental & Craniofacial Research (NIDCR), the University of Pittsburgh School of Dental Medicine will establish a new Research Training Program aimed at preparing the next generation of Craniofacial/Dental focused scientists. Major research foci at Pitt Dental are Craniofacial/Dental Genetics and Craniofacial/Dental Tissue Regeneration as well as translational research. Trainees will be included at both the pre-doctoral and post-doctoral levels.